Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jane A. Thanassi"'
Autor:
Xuan Yuan, Eleni Gavriilaki, Jane A. Thanassi, Guangwei Yang, Andrea C. Baines, Steven D. Podos, Yongqing Huang, Mingjun Huang, Robert A. Brodsky
Publikováno v:
Haematologica, Vol 102, Iss 3 (2017)
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement co
Externí odkaz:
https://doaj.org/article/076079ff9a2e4756996fe44833d94790
Autor:
Steven D. Podos, Howard Trachtman, Gerald B. Appel, Andrew S. Bomback, Bradley P. Dixon, Jack F.M. Wetzels, H. Terence Cook, Samir V. Parikh, Matthew C. Pickering, James Tumlin, Craig B. Langman, Liz Lightstone, C. John Sperati, Erica Daina, Koenraad Peter Bouman, Kara Rice, Jane A. Thanassi, Mingjun Huang, Carla Nester, Giuseppe Remuzzi
Publikováno v:
American Journal of Nephrology. 53:675-686
Introduction: C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who participated in two phase 2 stud
Autor:
Gerald B. Appel, Jack F.M. Wetzels, Mingjun Huang, Steven D. Podos, Jane A. Thanassi, Kara Rice, John Sperati, Giuseppe Remuzzi, Carla M. Nester, Craig B. Langman, Samir M. Parikh, Erica Daina, Jonathan J. Hogan, Bradley P. Dixon, Andrew S. Bomback, Koen Bouman, Liz Lightstone, James A. Tumlin, Howard Trachtman, Matthew C. Pickering, Terry Cook
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare, progressive kidney diseases requiring a biopsy for definite diagnosis. Both C3G and IC-MPGN are attributed to complement dysre
Autor:
Robert A. Brodsky, Steven D. Podos, Jane A. Thanassi, Eleni Gavriilaki, Xuan Yuan, Guangwei Yang, Yongqing Huang, Andrea C. Baines, Mingjun Huang
Publikováno v:
Haematologica
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement co
Autor:
Dhanalakshmi R. Nair, João M. Monteiro, Jane A. Thanassi, Michael J. Pucci, Guido Memmi, Mariana Luisa Pinho, Ambrose L. Cheung, Joseph D. Schwartzman
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:1876-1885
In a loss-of-viability screen using small molecules against methicillin-resistant Staphylococcus aureus (MRSA) strain USA300 with a sub-MIC of a β-lactam, we found a small molecule, designated DNAC-1, which potentiated the effect of oxacillin (i.e.,
Comparison of two commercial enzyme-linked immunosorbent assays for detection of complement factor D
Autor:
Dharaben Patel, Amanda Luu, Manuel Galvan, Guangwei Yang, Yongsen Zhao, Jane A. Thanassi, Mingjun Huang, Wengang Yang, Steven D. Podos
Publikováno v:
Molecular Immunology. 102:199-200
Autor:
Jane A. Thanassi, Dharaben Patel, Guangwei Yang, Steven D. Podos, Manuel Galvan, Yongsen Zhao, Mingjun Huang, Wengang Yang, Amanda Luu
Publikováno v:
Molecular Immunology. 102:219-220
Publikováno v:
Blood. 134:5763-5763
Introduction: Treatment of complement-associated disorders with the terminal complement inhibitor eculizumab brings a thousand-fold elevated risk of meningococcal disease due to blockage of serum bactericidal activity (SBA) and opsonophagocytosis aga
Autor:
Jason Allan Wiles, Wengang Yang, John Lahey, Dharaben Patel, Joanne Fabrycki, Xuan Yuan, Jane A. Thanassi, Steven D. Podos, Joel Charles Barrish, Hetal Kocinsky, Michael Geffner, Avinash Phadke, Mingjun Huang, Ifode Ajari, Manuel Galvan, Robert A. Brodsky, Yongsen Zhao, Amanda Luu, Guangwei Yang
Publikováno v:
Molecular Immunology. 89:200-201
Autor:
Michael J. Pucci, Melissa J. Leggio, Milind Deshpande, Barton James Bradbury, Jane A. Thanassi, Steven D. Podos
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:2860-2871
ACH-702, a novel isothiazoloquinolone (ITQ), was assessed for antibacterial activity against a panel of Gram-positive and Gram-negative clinical isolates and found to possess broad-spectrum activity, especially against antibiotic-resistant Gram-posit